Disease relevance of Maxillary Sinusitis

• CONCLUSION: Our results indicate that the combination of locally applied xylometazoline hydrochloride and budesonide reduces the incidence of radiological maxillary sinusitis and may reduce also that of nosocomial maxillary sinusitis in mechanically ventilated patients with multiple trauma [1].
• Azithromycin versus placebo in acute infectious rhinitis with clinical symptoms but without radiological signs of maxillary sinusitis [2].
• In the treatment of acute rhinitis with symptoms and signs of maxillary sinusitis but without empyema, treatment with azithromycin seems to result in a better cure rate after 10-12 days when compared with placebo [2].
• Paired sera from 97 patients with acute maxillary sinusitis were examined regarding antibodies to Branhamella catarrhalis [3].
• The use of co-trimazine once daily in acute otitis media and maxillary sinusitis in children [4].

High impact information on Maxillary Sinusitis

• Three vs 10 days of trimethoprim/sulfamethoxazole for acute maxillary sinusitis [5].
• Three vs 10 days of trimethoprim/sulfamethoxazole for acute maxillary sinusitis [6].
• PURPOSE: This multicenter study compared the clinical and bacteriologic efficacy of two oral antibiotics, cefuroxime axetil and amoxicillin/clavulanate, in the treatment of acute bacterial maxillary sinusitis [7].
• CONCLUSIONS: Our results indicate that cefuroxime axetil twice a day is as effective as amoxicillin/clavulanate three times a day in the treatment of acute bacterial maxillary sinusitis but produces fewer adverse effects [7].
• The results of a European trial in Sweden, Finland, and Iceland showed that loracarbef was clinically more effective than doxycycline in the treatment of acute bacterial maxillary sinusitis [8].

Chemical compound and disease context of Maxillary Sinusitis

• Azithromycin and amoxicillin in the treatment of acute maxillary sinusitis [9].
• Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with acute bacterial maxillary sinusitis [7].
• Oral levofloxacin was also similar in efficacy to amoxicillin/clavulanic acid or oral clarithromycin in patients with acute maxillary sinusitis treated for 7 to 14 days [10].
• Gallium-67 scanning in the differentiation of maxillary sinus carcinoma from chronic maxillary sinusitis [11].
• The results of this study suggest that clarithromycin is as effective and well tolerated as amoxycillin in the treatment of acute maxillary sinusitis [12].

Biological context of Maxillary Sinusitis

• Bacteriology and beta-lactamase activity in acute and chronic maxillary sinusitis [13].
• These findings demonstrate that experimental induction of acute maxillary sinusitis in rabbits does not increase lipid peroxidation as evidenced by MDA levels in the sinus mucosa, but does alter the activities of some antioxidant enzymes [14].
• The pharmacokinetics of the maxillary sinus fluid were studied in 42 patients (26 males and 16 females), suffering from chronic maxillary sinusitis, after oral administration of 0.5g or 1g cefaclor [15].
• OBJECTIVE: To compare the effectiveness of penicillin V with placebo in the treatment of adult patients with acute maxillary sinusitis in general practice [16].
• METHOD: In this prospective, multicentre, randomized, double-blind clinical trial, 501 adult outpatients seen in 17 otolaryngology offices with both symptoms and radiographic evidence of acute maxillary sinusitis randomly received oral ciprofloxacin (500 mg b.i.d.) or cefuroxime axetil (250 mg b.i.d.), each for 10 days [17].

Anatomical context of Maxillary Sinusitis

• Mucociliary activity and histopathology of sinus mucosa in experimental maxillary sinusitis: a comparison of systemic administration of antibiotic and antibiotic delivery by polylactic acid polymer [18].
• Three weeks afterwards he was readmitted with the findings of lower respiratory tract involvement, maxillary sinusitis, nasal septum perforation, p- and c-antineutrophil cytoplasmic antibody (ANCA) positivity, but normal complement, ANA, and anti-ds DNA levels, suggesting the diagnosis of WG [19].
• Antileukoprotease, an inhibitor of leukocyte elastase, was studied in paired sera from 12 patients with maxillary sinusitis [20].
• PATIENTS: 133 adult patients with a clinical diagnosis of acute maxillary sinusitis based on maxillary pain and raised values of either C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) [16].

Gene context of Maxillary Sinusitis

• An assessment of concentrations of soluble CD4 and CD8 receptors in serum before and after surgical treatment in patients with chronic maxillary sinusitis [21].
• RANTES is more prevalent in bacterial than in nonbacterial maxillary sinusitis: and P-selectin is preferentially up-regulated in diseased mucosae [22].
• Prevalence of etiologic bacteria and beta-lactamase-producing bacteria in acute and chronic maxillary sinusitis at Phramongkutklao Hospital [23].
• Twenty-four atopic children with allergic rhinitis, asthma and maxillary sinusitis were treated with a combination of cefuroxime 50-80 mg/kg/day and N-acetyl-cysteine 15-25 mg/kg/day administered intramuscularly for 10 days [24].
• 152 sinuses of children with acute maxillary sinusitis were roentgenographically examined with both a standard occipito-mental (OM) and an occipito-mental side (OMS) projection [25].

Analytical, diagnostic and therapeutic context of Maxillary Sinusitis

• Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis [26].
• DESIGN: This double-blind, randomized trial compared cefaclor with amoxicillin in the treatment of acute, recurrent, and chronic maxillary sinusitis using clinical evaluation, roentgenography, and microbiologic evaluation of antral aspirates [27].
• MATERIALS AND METHODS: Computed tomography and bone SPECT with Tc-99m HMDP were performed in 28 patients with odontogenic maxillary sinusitis [28].
• This multicentre, prospective study evaluated the efficacy and safety of 7-day oral moxifloxacin (400 mg/day) for treatment of acute maxillary sinusitis after first-line treatment failure (group 1), and acute sinusitis with high risk of complications (group 2) [29].
• The aim of the present study was to evaluate whether the results of such simple hematologic tests as erythrocyte sedimentation rate (ESR), white blood cell count (WBC) and C-reactive protein (CRP) could give any useful information about the causative agents in 176 patients with acute maxillary sinusitis (AMS) [30].

References